The present invention relates to compounds of formula Ia and formula Ib, as well as pharmaceutically acceptable compounds thereof, useful for the treatment of prostate cancer, breast cancer, colon cancer, pancreatic cancer, human chronic lymphocytic leukemia, melanoma and other cancers. Regarding salts: The present invention also includes pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula Ia or Formula Ib, or a pharmaceutically acceptable salt thereof. The invention disclosed herein also relates to methods for treating prostate cancer, breast cancer, ovarian cancer, liver cancer, kidney cancer, colon cancer, pancreatic cancer, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further a method of treating prostate cancer, breast cancer, colon cancer, pancreatic cancer, chronic lymphocytic leukemia, melanoma and other cancers, comprising a dual antagonist of PPARα and PPARδ. It relates to a method comprising the administration of a therapeutically effective amount of a compound. The compounds and pharmaceutical compositions of the present invention are also useful for the treatment of viral infections such as HCV infection and HIV infection. The invention disclosed herein is a method for preventing the onset and / or recurrence of acute and chronic myelogenous leukemia and other cancers, comprising administering a therapeutically effective amount of a dual antagonist of PPARα and PPARδ. It also relates to the method of inclusion. [Selection] Figure 1本発明は、前立腺癌、乳癌、大腸癌、膵臓癌、ヒト慢性リンパ球性白血病、黒色腫及びその他のガンの治療に有用な、式Ｉａ及び式Ｉｂの化合物、並びに薬学的に許容可能なその塩に関する： 【化１】 本発明は治療有効量の式Ｉａ又は式Ｉｂの化合物又は薬学的に許容可能なその塩を含む医薬組成物も含む。本明細書において開示される発明は前立腺癌、乳癌、卵巣癌、肝臓癌、腎臓癌、大腸癌、膵臓癌、ヒト慢性リンパ球性白血病、黒色腫及び他のガンの治療方法にも関する。本明細書において開示される発明は更に、前立腺癌、乳癌、大腸癌、膵臓癌、慢性リンパ球性白血病、黒色腫及び他のガンを治療する方法であって、ＰＰＡＲαとＰＰＡＲδの二重アンタゴニストである化合物の治療有効量の投与を含む方法に関する。本発明の化合物と医薬組成物はＨＣＶ感染症及びＨＩＶ感染症などのウイルス感染症の治療にも有用である。本明細書において開示される発明は、急性骨髄性白血病及び慢性骨髄性白血病並びに他のガンの発症及び／又は再
